Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 11/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.56 |
| ▸ | RAF1 | P04049 | 2/20 | 0.56 |
| ▸ | GCGR | P47871 | 9/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.56 |
| ▸ | FRK | P42685 | 2/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.56 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.53 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CIT | O14578 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6600561 | 0.85 | MAPK13 (0.56) | MAPK13MAPK12MAPK11MAPK14MAPK9 | |
| SCHEMBL5962371 | 0.78 | MAPK14 (0.51) | MAPK13MAPK12MAPK11MAPK14MAPK9 | |
| SCHEMBL8446904 | 0.77 | MAPK13 (0.57) | MAPK13MAPK12MAPK11MAPK14MAPK9 | |
| SCHEMBL7854909 | 0.75 | MAPK14 (0.52) | MAPK13MAPK12MAPK11MAPK14MAPK9 | |
| SCHEMBL4026498 | 0.75 | BRAF (0.54) | MAPK13MAPK12MAPK11MAPK14MAPK9 | |
| SCHEMBL6585626 | 0.74 | MAPK13 (0.51) | MAPK13MAPK12MAPK11MAPK14MAPK9 | |
| SCHEMBL6600321 | 0.74 | MAPK11 (0.60) | MAPK13MAPK12MAPK11MAPK14MAPK9 | |
| SCHEMBL14521876 | 0.73 | MAPK14 (0.53) | MAPK13MAPK12MAPK11MAPK14MAPK9 | |
| SCHEMBL6584089 | 0.73 | MAPK13 (0.51) | MAPK13MAPK12MAPK11MAPK14MAPK9 | |
| SCHEMBL19868925 | 0.72 | MAPK11 (1.00) | MAPK13MAPK12MAPK11MAPK14MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026336-B1 | 4-pyridinylimidazol-2-ylhydrocarbyl amine, (thio)urea, carbamic acid or sulfonamide derivatives, e.g., (2-(4-(4-Chloro-3-methoxy-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-carbamic acid tert-butyl ester; Raf kinase inhibitors for the treatment of neurotraumatic diseases | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-04-11 | — | — | US | claimed |
| EP-1396491-A2 | 2-substituted 4,5-diaryl-imidazoles and their use as p38 MAP kinase inhibitors | Novartis AG (CH) | 2004-03-10 | — | — | EP | claimed |
| EP-1232153-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-08-21 | — | — | EP | claimed |
| WO-2001038324-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-31 | — | — | WO | claimed |
| CN-1261885-A | 2-substituted 4, 5-diarylimidazoles | NOVARTIS AG (CH) | 2000-08-02 | — | — | CN | claimed |
| EP-0993456-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | Novartis AG (CH) | 2000-04-19 | — | — | EP | claimed |
| WO-1999001449-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | NOVARTIS AG (CH) | 1999-01-14 | — | — | WO | claimed |
| US-7026336-B1 | 4-pyridinylimidazol-2-ylhydrocarbyl amine, (thio)urea, carbamic acid or sulfonamide derivatives, e.g., (2-(4-(4-Chloro-3-methoxy-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-carbamic acid tert-butyl ester; Raf kinase inhibitors for the treatment of neurotraumatic diseases | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-04-11 | — | — | US | disclosed |
| EP-1232153-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-11-03 | — | — | EP | disclosed |
| EP-1396491-A2 | 2-substituted 4,5-diaryl-imidazoles and their use as p38 MAP kinase inhibitors | Novartis AG (CH) | 2004-03-10 | — | — | EP | disclosed |
| EP-1232153-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-08-21 | — | — | EP | disclosed |
| US-6300347-B1 | FOR THERAPY OF TUMOR NECROSIS FACTOR AND INTERLEUKIN-1 MEDIATED DISEASES SUCH AS RHEUMATOID ARTHRITIS AND DISEASES OF BONE METABOLISM, E.G. OSTEOPOROSIS | NOVARTIS AG (CH) | 2001-10-09 | — | — | US | disclosed |
| WO-2001038324-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-31 | — | — | WO | disclosed |
| CN-1261885-A | 2-substituted 4, 5-diarylimidazoles | NOVARTIS AG (CH) | 2000-08-02 | — | — | CN | disclosed |
| EP-0993456-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | Novartis AG (CH) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999001449-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | NOVARTIS AG (CH) | 1999-01-14 | — | — | WO | disclosed |